Moderna investors got two pieces of news this week that have nothing to do with the share price, and both arguably matter more than it. The company settled its patent disputes with GSK across the US and Europe, and Health Canada cleared both of its flu products. Neither came with a cheque attached — in the first case, that’s the point.
A settlement without a bill
GSK and Moderna have resolved claims GSK brought over Moderna’s COVID-19 and RSV vaccines, according to media reports. The two sides granted each other patent licences covering infectious diseases, and no payments fall due under the arrangement.
That combination — legal peace plus mutual access to patented technology — is what elevates the deal above a routine courtroom footnote. For Moderna, it removes a set of disputes from the board without creating a new payment obligation. The value of that cleaner starting position, though, will be settled by demand for the products in question and by how the wider business develops, not by the settlement itself.
Canada delivers a first
Health Canada’s approval covers mFLUSIVA, a seasonal mRNA flu shot, and mCOFLU, a combined influenza and COVID-19 vaccine. Both are cleared for adults aged 50 and over, and Canada becomes the first country to authorise either product.
For the bulls, this is the most concrete item on the list: a regulatory hurdle actually cleared, rather than a promise of one. The next test is the transition from approval to commercial traction. That handover — from a green light to revenue — is the yardstick investors should apply to whatever Moderna announces next.
Ebola candidate gets a WHO nod
On 4 November, a WHO technical advisory group recommended mRNA-1469, Moderna’s experimental Bundibugyo Ebola vaccine, for a Phase 2/3 efficacy trial. The planned study in the Democratic Republic of Congo remains subject to regulatory approvals.
The recommendation rests on results from the first clinical stage. It strengthens the development case only if the necessary authorisations follow and the trial confirms the encouraging early data. That makes this candidate a different kind of asset from the approved products — a research option rather than a near-term revenue line.
Should investors sell immediately? Or is it worth buying Moderna?
The quarter behind the rally
The numbers that set off the share price move came on Friday. Moderna reported third-quarter 2026 revenue of $1.3 billion and a net profit of $162 million. Revenue rose 29% year on year, and the company lifted its full-year revenue growth guidance to 15%–25%.
That pairing of delivered growth and a raised target explains the attention. The guidance, however, remains a promise about future trading, and the bar is now higher: the loftier the expectation, the more the coming results have to do the confirming.
Profit-taking, not a verdict
On Tuesday the stock gave back 6.1%, with media reports pointing to profit-taking after the post-earnings rally and to valuation concerns, compounded by a weaker broader market that weighed on volatile biotech names.
The pullback is best read as the tension between good corporate news and the question of what price is right for it — not as a judgment on the quarter. Anyone assessing Moderna should weight the business trajectory more heavily than the tempo of any single session.
What actually decides the story
Weighing it all up, the operational advances carry the day — provided Moderna converts the Canadian approvals into commercial ground and delivers on its raised expectations. The GSK truce and the Health Canada decisions give that view something solid to stand on. The real proving ground is how much durable business Moderna builds from them.
Ad
Moderna Stock: Buy or Sell?! New Moderna Analysis from November 11 delivers the answer:
The latest Moderna figures speak for themselves: Urgent action needed for Moderna investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 11.
Moderna: Buy or sell? Read more here...
